The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Clinical management of adrenocortical carcinoma
Abstract
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy, and most of the diagnostic and therapeutic strategies are not fully established according to criteria of evidence-based medicine. However, recently collaborative efforts (e.g. International Consensus Conference 2003 and networks like the European Network for the Study of Adrenal Tumours (ENSAT)) have significantly advanced the field. This article summarizes current standards in the management of ACC. In patients with suspected ACC a thorough endocrine and imaging work-up is followed by complete (Ro) resection of the tumour by an expert surgeon and initiation of adjuvant mitotane. In advanced disease not amenable to radical resection, cytotoxic drugs will be added to mitotane. The most promising regimens (etoposide, doxorubicin, cisplatin plus mitotane and streptozotocin plus mitotane) are currently compared in an international phase-III trial. Several targeted therapies are under investigation (e.g. IGF-1 inhibitors, sunitinib, sorafenib) and may lead to new treatment options.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median age of diagnosis is in the fifth to sixth decade, with the German ACC Registry reporting a median age at diagnosis of 46 years (9).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Another third present with nonspecific symptoms due to local tumor growth, such as abdominal or flank pain, abdominal fullness, or early satiety (9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“For 40% to 60% of patients, the major presenting complaints are symptoms and signs of hormone excess (3, 9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“At the time of presentation, ACCs are generally large tumors, measuring on average 10 to 13 cm (9, 85, 89).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Although earlier studies found 49% of patients with metastatic disease (stage 4) at presentation, currently only 25% to 30% of patients present with metastatic disease (9, 13, 25).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
Citations
Cites
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
Bovio, S., Cataldi, A., Reimondo, G., Sperone, P., Novello, S., Berruti, A., Borasio, P., Fava, C., Dogliotti, L., Scagliotti, G. V., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344099 · Cited by 712
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationCharacterization of adrenal masses using unenhanced CT: an analysis of the CT literature
Boland, G. W., Lee, M. J., Gazelle, G. S., Halpern, E. F., McNicholas, M. M., & Mueller, P. R. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.1.9648789 · Cited by 693
Flagged first, then by citations
2 of the 106 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Bergenstal, 1959, Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD, Transactions of American Physicians, 72, 341
Cited by
Sorted by citations
Items 101–200 of 348
A review of mitotane in the management of adrenocortical cancer
Rivero, J. D., Else, T., Johnson, J. E. H., Kiseljak‐Vassiliades, K., Raj, N. P., Reidy‐Lagunes, D. L., Srinivas, S., Gilbert, J., Vaidya, A., Aboujaoude, E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae084 · Cited by 24
Adrenocortical carcinoma presenting as varicocele and renal vein thrombosis: a case report
Cheungpasitporn, W., Horne, J. M., & Howarth, C. B. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-337 · Cited by 24
Minimally Invasive Surgery for Primary and Metastatic Adrenal Malignancy
Kiernan, C. M., & Lee, J. E. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2018.11.011 · Cited by 24
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
Haider, M. S., Ahmad, T., Gröll, J., Scherf‐Clavel, O., Kroiß, M., & Luxenhofer, R. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00700-5 · Cited by 28
Development of a Pharmacokinetic Model of Mitotane
Kerkhofs, T. M. A., Derijks, L. J. J., Ettaieb, H., den Hartigh, J., Neef, K., Gelderblom, H. A. J., Guchelaar, H., & Haak, H. R. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000102 · Cited by 24
Srougi, V., de Bessa, J., Tanno, F. Y., Ferreira, A. M., Hoff, A. O., Neto, J. E. B., de Almeida, C. M., Almeida, M. Q., Mendonca, B. B., Nahas, W. C., et al. (2017) · International braz j urol · doi:10.1590/s1677-5538.ibju.2017.0095 · Cited by 24
Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma
Clay, M. R., Pinto, E. M., Fishbein, L. M., Else, T., & Kiseljak‐Vassiliades, K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab866 · Cited by 24
Sasaki, S., Yasuda, T., Kaneto, H., Otsuki, M., Tabuchi, Y., Fujita, Y., Kubo, F., Tsuji, M., Fujisawa, K., Kasami, R., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7726 · Cited by 23
Surgical Management of Adrenocortical Carcinoma
Ranvier, G. G. F., & Inabnet, W. B. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.008 · Cited by 22
Butler, C., Butler, W. M., & Rizvi, A. A. (2010) · Endocrine Practice · doi:10.4158/ep09295.cr · Cited by 22
Ip, J. C. Y., Pang, T., Glover, A. R., Soon, P. S. H., Zhao, J., Clarke, S. J., Robinson, B. G., Gill, A. J., & Sidhu, S. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0392 · Cited by 25
Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19
Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
Oddie, P. D., Albert, B. B., Hofman, P. L., Jefferies, C., Laughton, S. J., & Carter, P. J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0059 · Cited by 21
The Immunotherapy Landscape in Adrenocortical Cancer
Pegna, G. J., Roper, N., Kaplan, R. N., Bergsland, E. K., Kiseljak‐Vassiliades, K., Habra, M. A., Pommier, Y. G., & Rivero, J. D. (2021) · Cancers · doi:10.3390/cancers13112660 · Cited by 22
Rose, J. B., Vergneau‐Grosset, C., Steffey, M. A., Johnson, E. G., Chen, V. S., Mohr, F. C., Harvey, C., & Guzman, D. S.-M. (2016) · Journal of Exotic Pet Medicine · doi:10.1053/j.jepm.2016.06.010 · Cited by 21
Stewart, P. M., & Newell-Price, J. D. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00015-0 · Cited by 24
New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma
Stigliano, A., Cerquetti, L., Lardo, P., Petrangeli, E., & Toscano, V. (2017) · Oncology Reports · doi:10.3892/or.2017.5427 · Cited by 20
Ettaieb, M. H. T., Duker, J. C., Feelders, R. A., Corssmit, E. P. M., van Oordt, C. W. M. D. H., Timmers, H. J. L. M., Kerstens, M. N., Wilmink, J. W., ZELISSEN, P. M. J., Havekes, B., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0270-5 · Cited by 19
Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma
Liu‐Chittenden, Y., Patel, D., Gaskins, K., Giordano, T. J., Assié, G., Bertherat, J. Y., & Kebebew, E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1781 · Cited by 19
mRNA and microRNA expression patterns in adrenocortical cancer.
Zsippai, A., Szabó, D. R., Szabó, P. M., Tömböl, Z., Bendes, M. R., Nagy, Z., Rácz, K., & Igaz, P. (2011) · PubMed Central · Cited by 19
Androgen- and Estrogen-Secreting Adrenal Cancers
Cavlan, D., Bharwani, N., & Grossman, A. B. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.016 · Cited by 19
Approach to the Patient with Subclinical Cushing’s Syndrome
Ivović, M., Marina, L., Šojat, A. S., Tančić‐Gajić, M., Arizanović, Z., Kendereški, A., & Vujović, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200813134328 · Cited by 18
Pronio, A., Piroli, S., Ciamberlano, B., Alessandro, D. L., Antonino, M., Barretta, A., Mazzesi, G., Massimo, R., & Montesani, C. (2015) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2015.07.008 · Cited by 18
Epidemiology of Adrenocortical Carcinoma
Faßnacht, M., & Allolio, B. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_3 · Cited by 18
Self-citationŁawnicka, H., Kowalewicz‐Kulbat, M., Sicińska, P., Kazimierczuk, Z., Grieb, P., & Stepien, H. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-0960-1 · Cited by 18
Mornar, A., Sertić, M., Turk, N., Nigović, B., & Koršić, M. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2696 · Cited by 18
GnRH antagonist treatment of malignant adrenocortical tumors
Doroszko, M., Chruściel, M., Stelmaszewska, J., Ślężak, T., Anisimowicz, S., Plöckinger, U., Quinkler, M. O., Bonomi, M., Wołczyński, S., Huhtaniemi, I. T., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0399 · Cited by 18
Cancer of the Endocrine System
Schneider, D. F., Mazeh, H., Lubner, S. J., Jaume, J. C., & Chen, H. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00071-0 · Cited by 18
Rowe, N. E., Kumar, R., Schieda, N., Siddiqi, F. S., McGregor, T. B., McAlpine, K., Violette, P. D., Bathini, V., Eng, M. K., & Izard, J. (2023) · Canadian Urological Association Journal · doi:10.5489/cuaj.8248 · Cited by 18
Preclinical Models of Adrenocortical Cancer
Sedlack, A. J. H., Hatfield, S. J., Kumar, S., Arakawa, Y., Roper, N., Sun, N.-Y., Nilubol, N., Kiseljak‐Vassiliades, K., Hoang, C. D., Bergsland, E. K., et al. (2023) · Cancers · doi:10.3390/cancers15112873 · Cited by 17
Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey
Lim, J. S., Lee, S., Kim, J. H., Kim, J. H., & _, _. (2020) · Endocrine Connections · doi:10.1530/ec-20-0196 · Cited by 17
Catalano, R., Giardino, E., Treppiedi, D., Mangili, F., Morelli, V., Elli, F. M., Serban, A. L., Luconi, M., Mannelli, M., Spada, A., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.022 · Cited by 16
Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines
Gentilin, E., Molè, D., Gagliano, T., Minoia, M., Ambrosio, M. R., Uberti, E. C. D., & Zatelli, M. C. (2014) · Reproductive Toxicology · doi:10.1016/j.reprotox.2014.01.008 · Cited by 16
Adrenocortical carcinoma: What the surgeon needs to know. Case report and literature review
Benassai, G., Desiato, V., Benassai, G., Bianco, T., Sivero, L., Compagna, R., Vigliotti, G., Limite, G., Amato, B., & Quarto, G. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.030 · Cited by 16
Incomplete Pattern of Steroidogenic Protein Expression in Functioning Adrenocortical Carcinomas
Pereira, S. S., Costa, M. M., Gómez-Sánchez, C. E., Monteiro, M. P., & Pignatelli, D. (2020) · Biomedicines · doi:10.3390/biomedicines8080256 · Cited by 17
Subramanian, C., & Cohen, M. S. (2021) · Surgery · doi:10.1016/j.surg.2021.04.049 · Cited by 16
Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring
Kerkhofs, T. M. A., Derijks, L. J. J., Ettaieb, M. H. T., Eekhoff, E. M. W., Neef, C., Gelderblom, H. A. J., den Hartigh, J., Guchelaar, H., & Haak, H. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0388 · Cited by 16
Riedmeier, M., Antonini, S. R. R., Brandalise, S. R., Costa, T. E. J. B., Daiggi, C. M. M., de Figueiredo, B. C., de Krijger, R. R., Rodrigues, K. E. D. S., Deal, C., Rivero, J. D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae038 · Cited by 15
Brown, T. C., Nicolson, N. G., Korah, R. M., & Carling, T. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.01.051 · Cited by 15
Personalized Care of Patients with Adrenocortical Carcinoma: A Comprehensive Approach
Miller, B. S., & Else, T. (2017) · Endocrine Practice · doi:10.4158/ep161719.ra · Cited by 15
Endocrine oncology in pregnancy.
Lansdown, A., & Rees, D. (2011) · Best practice & research. Clinical endocrinology & metabolism · doi:10.1016/j.beem.2011.06.011 · Cited by 20
Satoh, K., Patel, D., Dieckmann, W., Nilubol, N., & Kebebew, E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4813-8 · Cited by 15
Gaitanidis, A., Wiseman, D., Lakis, M. E., Nilubol, N., Kebebew, E., & Patel, D. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25760 · Cited by 14
Molecular markers and targeted therapies for adrenocortical carcinoma
Xu, Y., Qi, Y., Zhu, Y., Ning, G., & Huang, Y. (2013) · Clinical Endocrinology · doi:10.1111/cen.12358 · Cited by 13
Disorders of the adrenal cortex: Genetic and molecular aspects
Pitsava, G., Maria, A. G., & Faucz, F. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.931389 · Cited by 13
Sun, N.-Y., Kumar, S., Kim, Y. S., Varghese, D. G., Mendoza, A., Nguyen, R., Okada, R., Reilly, K. M., Widemann, B. C., Pommier, Y. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60649-w · Cited by 12
Doghman, M., Axelson, M., & Lalli, E. (2011) · Europe PMC (PubMed Central) · Cited by 12
SCHTEINGART, D. E., Sinsheimer, J. E., Benitez, R. S., Homan, D. F., Johnson, T. D., & Counsell, R. E. (2012) · PubMed · Cited by 12
Ganeshan, D., Bhosale, P., & Kundra, V. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.8282 · Cited by 12
Werner, R. A., Kroiß, M., Nakajo, M., Mügge, D. O., Hahner, S., Faßnacht, M., Schirbel, A., Bluemel, C., Higuchi, T., Papp, L., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0970-1 · Cited by 11
Hasanovic, A., Simsir, M., Choveau, F. S., Lalli, E., & Mus‐Veteau, I. (2020) · Biomedicines · doi:10.3390/biomedicines8080251 · Cited by 10
Cancer of the Endocrine System
Asban, A. A., Patel, A. J., Reddy, S., Wang, T., Balentine, C. J., & Chen, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00068-2 · Cited by 10
Lin, T.-Y., Lin, K., Kuo, H., Huang, K., Wang, C., Lin, Y., Shih, S., & Liang, P. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac091 · Cited by 9
Pennanen, M., Raade, M., Louhimo, J. M., Sane, T., Heiskanen, I., Arola, J. T., & Haglund, C. H. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201513 · Cited by 9
A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment
Paolo, A. D., Ciofi, L., Bacca, A., & Bernini, G. P. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1552502 · Cited by 9
Nonfunctional adrenocortical carcinoma initially presenting as retroperitoneal hemorrhage
Kashiwagi, S., Amano, R., Onoda, N., Noda, S., Hirata, K., Asano, Y., Kurata, K., Miura, K., Yamazoe, S., Kimura, K., et al. (2015) · BMC Surgery · doi:10.1186/s12893-015-0031-3 · Cited by 9
Current issues in the diagnosis and management of adrenocortical carcinomas
Kassi, E. N., Kaltsas, G., Zografos, G., & Chrousos, G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.6 · Cited by 9
Tumeurs malignes de la surrénale : Contribution du CCAFU au référentiel INCa
Sèbe, P., Rigaud, J., Avancès, C., Brunaud, L., Caillard, C., Camparo, P., Carnaille, B. M. L., Culine, S., Durand, X., Mathonnet, M., et al. (2010) · The French Journal of Urology · doi:10.1016/s1166-7087(10)70047-6 · Cited by 9
Situ, Y., Liang, Q., Zeng, Z., Chen, J., Shao, Z., Xu, Q., Lu, X., Cui, Y., Zhang, J., Lu, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1089531 · Cited by 8
KIF11 is a potential prognostic biomarker and therapeutic target for adrenocortical carcinoma
Zhou, Y., Chen, X. '., Li, B., Li, Y., & Zhang, B. (2023) · Translational Andrology and Urology · doi:10.21037/tau-22-706 · Cited by 8
Machine Learning–Based Survival Prediction Tool for Adrenocortical Carcinoma
Saygılı, E. S., Elhassan, Y., Prete, A., Lippert, J., Altieri, B., & Ronchi, C. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf096 · Cited by 9
Kouyama, R., Hiraishi, K., Sugiyama, T., Izumiyama, H., Yoshimoto, T., Akashi, T., Kihara, K., Homma, K., Shibata, H., & Hirata, Y. (2011) · Endocrine Journal · doi:10.1507/endocrj.k11e-026 · Cited by 8
MicroRNA Era: The Importance for Diagnosis and Prognosis of Adrenocortical Tumors
Neto, J. E. B., & Latronico, A. C. (2014) · BioMed Research International · doi:10.1155/2014/381917 · Cited by 8
Alghulayqah, A., ALGhasab, N. S., Amin, T., Alkahtani, N. S., Farhat, R., & Alzahrani, A. S. (2017) · Medicine · doi:10.1097/md.0000000000006751 · Cited by 8
Epithelioid angiomyolipoma mimicking adrenal cortical carcinoma: A diagnostic pitfall
Komarowska, H., Bednarek-Rajewska, K., KAŃSKI, M., Janicka‐Jedyńska, M., Gut, P., & Ruchała, M. (2015) · Oncology Letters · doi:10.3892/ol.2015.3543 · Cited by 7
Uruç, F., Ürkmez, A., Yüksel, Ö. H., Şahin, A., & Verit, A. (2015) · Canadian Urological Association Journal · doi:10.5489/cuaj.2867 · Cited by 7
Metastatic adrenal cortical carcinoma to T12 vertebrae
Lee, D. K., Yanamadala, V., Shankar, G. M., & Shin, J. H. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.11.009 · Cited by 7
Surgical treatment of potentially primary malignant adrenal tumors: an unresolved issue
Zografos, G. N., Perysinakis, I., Kyrodimou, E., Kassi, E. N., & Kaltsas, G. (2015) · HORMONES · doi:10.1007/bf03401380 · Cited by 7
ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
Yarom, N., Stewart, D., Avruch, L. I., Malik, R. K., Wells, J., & Jonker, D. J. (2011) · PubMed · Cited by 7
Diagnosis and Management of Hereditary Adrenal Cancer
Angelousi, A. G., Zilbermint, M. F., Berthon, A. S., Espiard, S., & Stratakis, C. A. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-29998-3_8 · Cited by 7
Identification of Seven Aberrantly Methylated and Expressed Genes in Adrenocortical Carcinoma
Xiao, H., He, W., Chen, P., Xu, D., Zeng, G., Li, Z. Y., Huang, M., Wang, X., DiSanto, M. E., & Zhang, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00472 · Cited by 7
Evaluation and management of adrenal neoplasms: endocrinologist and endocrine surgeon perspectives
Mazzaglia, P. J., Varghese, J. M., & Habra, M. A. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02464-z · Cited by 9
Lived experience of people with adrenocortical carcinoma and associated adrenal insufficiency
Yeoh, P., Czuber‐Dochan, W., Aylwin, S. J. B., & Sturt, J. A. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.341 · Cited by 7
Update on Adrenocortical Carcinoma
Sarrafan‐Chaharsoughi, Z., Anari, P. Y., Malayeri, A. A., Naraev, B. G., & Rivero, J. D. (2025) · Urologic Clinics of North America · doi:10.1016/j.ucl.2025.01.009 · Cited by 6
Atallah, S., Alassaf, H., Xu, Y., & El-Sayed, S. M. (2017) · Current Oncology · doi:10.3747/co.24.3533 · Cited by 6
The case series of functional adrenal tumors
Mbouché, L. O., Ngallè, F. G. E., Sando, Z., Choukem, S. P., & Angwafo, F. (2020) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2020.05.097 · Cited by 6
Garay-Lechuga, D., Pérez-Soto, R. H., Hernández-Acevedo, J. D., Butrón-Hernández, D., Sierra‐Salazar, M., Pantoja‐Millán, J. P., Herrera, M. F., & Velázquez‐Fernández, D. (2021) · Surgery · doi:10.1016/j.surg.2021.04.042 · Cited by 6
Surgical management of metastatic adrenocortical carcinoma
Passman, J. E., Amjad, W., Ginzberg, S. P., Ballester, J. M. S., Finn, C. B., & Wachtel, H. (2023) · World Journal of Surgery · doi:10.1002/wjs.12014 · Cited by 7
Incidentalomes de la glande surrénale : ne pas méconnaître les tumeurs à risque
Tabarin, A. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.01.006 · Cited by 6
Straka, M., Soumarová, R., Bulejčík, J., Baník, M., Pura, M., & Skrovina, M. (2013) · Biomedical Papers · doi:10.5507/bp.2013.040 · Cited by 6
Towards a Virtual Research Environment for International Adrenal Cancer Research
Sinnott, R., & Stell, A. (2011) · Procedia Computer Science · doi:10.1016/j.procs.2011.04.118 · Cited by 6
Sarcopenia is Associated with Reduced Survival following Surgery for Adrenocortical Carcinoma
Jong, M. C. D., Patel, N., Hassan-Smith, Z. K., Mihai, R., & Khan, S. (2021) · Endocrine Research · doi:10.1080/07435800.2021.1954942 · Cited by 6
Plant Natural Compounds in the Treatment of Adrenocortical Tumors
Manso, J., Sharifi‐Rad, J., Zam, W., Fokou, P. V. T., Martorell, M., & Pezzani, R. (2021) · International Journal of Endocrinology · doi:10.1155/2021/5516285 · Cited by 6
Resektionsstrategie bei Nebennierenrindenkarzinomen
Schimmack, S. J., & Strobel, O. (2018) · Der Chirurg · doi:10.1007/s00104-018-0712-4 · Cited by 6
The diagnosis and treatment of adrenocortical carcinoma in pregnancy: a case report
Zhang, Y., Yuan, Z., Qiu, C., Li, S., Zhang, S., & Fang, Y. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-2737-1 · Cited by 7
Jannello, L. M. I., Siech, C., Baudo, A., de ANGELIS, M., Bello, F. D., Goyal, J. A., Tian, Z., Luzzago, S., Mistretta, F. A., LORENZIS, E. D., et al. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04185-x · Cited by 5
Steroid profiling in adrenal disease
Mu, D., Sun, D., Qian, X., Ma, X., Qiu, L., Cheng, X., & Yu, S. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117749 · Cited by 5
Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study
Kamiński, K., Blatkiewicz, M., Szyszka, M., Olechnowicz, A., Komarowska, H., Klimont, A., Wierzbicki, T., Karczewski, M., Ruchała, M., & Ruciński, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168721 · Cited by 6
Adrenal cortical carcinoma with tumor thrombus extension into the right atrium: A case report
Wang, Y., Zhou, F., Pan, H., & Jin, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4502 · Cited by 5
Molecular genetic markers and criteria for the prediction of adrenocortical carcinoma
Selivanova, L. S., Александровна, Р. А., Васильевна, Б. А., Tertychnyy, A. S., Beltsevich, D. G., AIu, A., & Mel'nichenko, G. A. (2019) · Russian Journal of Archive of Pathology · doi:10.17116/patol20198105192 · Cited by 5
The prognosis difference between elderly and younger patients with adrenocortical carcinoma
He, S., Huang, X., Zhao, P., & Zhang, P. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1029155 · Cited by 5
Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma
Passman, J. E., Amjad, W., Ballester, J. M. S., Ginzberg, S. P., & Wachtel, H. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14533-w · Cited by 6
The role of steroid metabolome analysis for the diagnosis and follow-up of adrenocortical tumors
Chortis, V. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02869-9 · Cited by 5
Kim, D. S., Murvelashvili, N., Hamidi, O., & Jia, L. (2022) · International Journal of Surgical Pathology · doi:10.1177/10668969221117246 · Cited by 4
Hescot, S., Faron, M., Kordahi, M., Cao, C. D., Naman, A., Lamartina, L., Hadoux, J., Leboulleux, S., Pattou, F. N., Aubert, S., et al. (2022) · Cancers · doi:10.3390/cancers14092225 · Cited by 4
Minimally invasive adrenalectomy for adrenocortical cancers: A systematic review
Pirzada, F. M., & Kumar, R. (2025) · Indian Journal of Urology · doi:10.4103/iju.iju_343_24 · Cited by 4
Adrenal Cortex Tumors and Hyperplasias
Pignatelli, D. (2011) · InTech eBooks · doi:10.5772/19108 · Cited by 4
Current criteria for the diagnosis of adrenocortical carcinoma
Selivanova, L. S., Александровна, Р. А., Kovalenko, Y. A., Васильевна, Б. А., Tertychnyy, A. S., Beltsevich, D. G., AIu, A., & Mel'nichenko, G. A. (2019) · Russian Journal of Archive of Pathology · doi:10.17116/patol20198103166 · Cited by 4
IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma
Kumar, A., Bellayr, I. H., Singh, H. S., & Puri, R. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246632 · Cited by 4
Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes
Zografos, G., Kassi, E. N., Parianos, C., Kyriakopoulos, G., Kostakis, I. D., Ansari, N. N., Aggeli, C., Dimitriadi, A., Angelousi, A. G., Papavassiliou, A. G., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1666-9026 · Cited by 4
Metadata
- Authors
- Fassnacht, M., & Allolio, B.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Fassnacht, Martin
- ORCID
- Fassnacht, Martin
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 23
- Issue
- 2
- Pages
- 273-289
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W2066923659
- Cited by
- 349
- References
- 106
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 20 · 2023: 24 · 2022: 16 · 2021: 24 · 2020: 20 · 2019: 13 · 2018: 21 · 2017: 12 · 2016: 22 · 2015: 30 · 2014: 15 · 2013: 18 · 2012: 33
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Krebshilfe
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- adrenocortical carcinoma, adrenalectomy, cytotoxic chemotherapy, etoposide, doxorubicin, cisplatin, streptozotocin, targeted therapy, sunitinib, sorafenib, diagnostic workup, advanced disease
- MeSH terms
- Adrenal Cortex Hormones, Adrenal Cortex Neoplasms, Animals, Humans, Neoplasm Staging, Prognosis, Adrenocortical Carcinoma, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
